Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Status:
Completed
Trial end date:
2019-11-13
Target enrollment:
Participant gender:
Summary
Multicenter phase II study on trabectedin in patients advanced uterine and ovarian
carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable
toxicity. Disease response evaluation will be assessed every 9 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Fondazione Policlinico Universitario Agostino Gemelli IRCCS